DETECTION OF ADENYLATE CYCLASE
    1.
    发明申请
    DETECTION OF ADENYLATE CYCLASE 审中-公开
    检测腺苷酸环化酶

    公开(公告)号:US20130210031A1

    公开(公告)日:2013-08-15

    申请号:US13878378

    申请日:2011-11-08

    IPC分类号: G01N33/569

    摘要: One major problem in diagnosis methods presently available for anthrax is that these methods require several days to produce a result, are rendered unusable after antibiotic use, or are not quantifiable. The only existing treatment for anthrax requires administration soon after infection at a time when patients are exhibiting only mild flu-like symptoms. Thus, by the time a diagnosis is made a patient may be days beyond the time when treatment would be effective. The present invention reduces diagnosis time to as little as four hours providing same day identification of anthrax radically increasing the odds of delivering proper treatment and patient recovery. The rapid identification of anthrax edema factor activity exhibited by the invention is also amenable to in vivo screening protocols for the discovery and development of anthrax vaccines, anti-toxins and edema factor inhibitors. The invention isolates and concentrates edema factor and edema toxin from nearly any sample. By capitalizing on the adenylate cyclase activity of edema factor the invention amplifies output signals producing reliable detection of low concentrations of edema factor previously unachievable. The invention involves novel purification and detection techniques and substrates for rapid, reproducible, and quantitative measurements of anthrax edema factor, and other adenylate cyclases in biological samples.

    摘要翻译: 目前可用于炭疽的诊断方法中的一个主要问题是这些方法需要几天才能产生结果,在使用抗生素后不能使用,或不能量化。 炭疽病唯一现有的治疗方法需要在感染后立即进行治疗,当时患者只出现轻微的流感样症状。 因此,在进行诊断的时候,患者可以是治疗有效的时间。 本发明将诊断时间缩短至少于4小时,同时提供炭疽的同一天鉴定,从而大大增加了提供适当治疗和患者恢复的几率。 本发明显示的炭疽水肿因子活性的快速鉴定也适用于发现和发展炭疽疫苗,抗毒素和水肿因子抑制剂的体内筛选方案。 本发明从几乎任何样品中分离并浓缩水肿因子和水肿毒素。 通过利用水肿因子的腺苷酸环化酶活性,本发明放大了产生可靠检测低浓度水肿因子的输出信号,这是先前无法实现的。 本发明涉及用于快速,可重复和定量测量生物样品中炭疽水肿因子和其他腺苷酸环化酶的新型纯化和检测技术和底物。

    DETECTION OF ANTHRAX PATHOGENICITY FACTORS
    2.
    发明申请
    DETECTION OF ANTHRAX PATHOGENICITY FACTORS 有权
    检测ANTHRAX致病因子

    公开(公告)号:US20120122123A1

    公开(公告)日:2012-05-17

    申请号:US11675233

    申请日:2007-02-15

    IPC分类号: G01N33/566 G01N21/64 C12M1/34

    摘要: One major problem in diagnosis methods presently available for anthrax is that these methods require several days to produce a result. The only existing treatment for anthrax requires administration soon after infection at a time when patients are exhibiting only mild flu-like symptoms. Thus, a patient may be days beyond the time when treatment would be effective by the time a diagnosis is made. The present invention reduces diagnosis time to as little as four hours providing same day identification of anthrax radically increasing the odds of delivering proper treatment and patient recovery. The rapid identification of anthrax lethal factor activity exhibited by the instant invention is also amenable to in vivo screening protocols for the discovery and development of anthrax vaccines and lethal factor inhibitors. The instant invention isolates and concentrates lethal factor and lethal toxin from nearly any biological sample. By capitalizing on the endopeptidase activity of lethal factor the present invention amplifies output signals producing reliable detection of picomolar concentrations of lethal factor. The instant invention involves novel purification and detection techniques and substrates for rapid, reproducible, and quantitative measurements of anthrax lethal factor in biological samples.

    摘要翻译: 目前可用于炭疽的诊断方法的一个主要问题是这些方法需要几天才能产生结果。 炭疽病唯一现有的治疗方法需要在感染后立即进行治疗,当时患者只出现轻微的流感样症状。 因此,患者可能是在诊断时治疗有效的时间。 本发明将诊断时间缩短至少于4小时,同时提供炭疽的同一天鉴定,从而大大增加了提供适当治疗和患者恢复的几率。 本发明显示的炭疽致死因子活性的快速鉴定也适用于发现和发展炭疽疫苗和致死因子抑制剂的体内筛选方案。 本发明从几乎任何生物样品中分离和浓缩致死因子和致死毒素。 通过利用致死因子的内肽酶活性,本发明扩增了产生对皮摩尔浓度致死因子的可靠检测的输出信号。 本发明涉及用于生物样品中炭疽致死因子的快速,可重复和定量测量的新颖的纯化和检测技术和底物。

    Detection of anthrax pathogenicity factors
    3.
    发明授权
    Detection of anthrax pathogenicity factors 有权
    检测炭疽致病因子

    公开(公告)号:US08663926B2

    公开(公告)日:2014-03-04

    申请号:US11675233

    申请日:2007-02-15

    摘要: One major problem in diagnosis methods presently available for anthrax is that these methods require several days to produce a result. The only existing treatment for anthrax requires administration soon after infection at a time when patients are exhibiting only mild flu-like symptoms. Thus, a patient may be days beyond the time when treatment would be effective by the time a diagnosis is made. The present invention reduces diagnosis time to as little as four hours providing same day identification of anthrax radically increasing the odds of delivering proper treatment and patient recovery. The rapid identification of anthrax lethal factor activity exhibited by the instant invention is also amenable to in vivo screening protocols for the discovery and development of anthrax vaccines and lethal factor inhibitors. The instant invention isolates and concentrates lethal factor and lethal toxin from nearly any biological sample. By capitalizing on the endopeptidase activity of lethal factor the present invention amplifies output signals producing reliable detection of picomolar concentrations of lethal factor. The instant invention involves novel purification and detection techniques and substrates for rapid, reproducible, and quantitative measurements of anthrax lethal factor in biological samples.

    摘要翻译: 目前可用于炭疽的诊断方法的一个主要问题是这些方法需要几天才能产生结果。 炭疽病唯一现有的治疗方法需要在感染后立即进行治疗,当时患者仅出现轻微的流感样症状。 因此,患者可能是在诊断时治疗有效的时间。 本发明将诊断时间缩短至少于4小时,同时提供炭疽的同一天鉴定,从而大大增加了提供适当治疗和患者恢复的几率。 本发明显示的炭疽致死因子活性的快速鉴定也适用于发现和发展炭疽疫苗和致死因子抑制剂的体内筛选方案。 本发明从几乎任何生物样品中分离和浓缩致死因子和致死毒素。 通过利用致死因子的内肽酶活性,本发明扩增了产生对皮摩尔浓度致死因子的可靠检测的输出信号。 本发明涉及用于生物样品中炭疽致死因子的快速,可重复和定量测量的新颖的纯化和检测技术和底物。